Key facts
- It has raised $198.3M across 5 recorded rounds; the latest was Early Stage VC ($38.4M) in Mar 2026.
- Notable investors include GV, Peter Thiel, What If Ventures, Casdin Capital, G9 Ventures — 17 tracked in total.
- TMRW Life Sciences has filed 6 Form Ds with the SEC since 2019, most recently Jul 2024 ($28.2M sold to 69 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for TMRW Life Sciences
Funding rounds
5 roundsAbout TMRW Life Sciences
Operator of a fertility technology company intended to provide safety and transparency to modernize and transform egg and embryo storage. The company's technology transforms and modernizes the specimen management process using technology, automation, robotics, intuitive touchscreen software, and full-time remote monitoring that reimagines eggs and embryo handling, enabling clinics to achieve embryologist advancements in IVF technology.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 82
- Website
- tmrwlifesciences.com/
- Ownership
- Privately Held (backing)
TMRW Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TMRW Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TMRW Life Sciences in its N-PORT filings yet. We sweep new filings monthly.